ReviewNanoscale2014
Messenger RNA (mRNA) nanoparticle tumour vaccination.
Review in Nanoscale, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 80 citations in OpenAlex.
- Non-interfacial self-assembly of synthetic protocells.Biomaterials research · 2023Article
- mRNA nanomedicine: Design and recent applications.Exploration (Beijing, China) · 2022Review
- Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects.Journal of nanobiotechnology · 2022Review
- Bacterial outer membrane vesicles as a candidate tumor vaccine platform.Frontiers in immunology · 2022Review
- Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.Advanced drug delivery reviews · 2021Review
- Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.International journal of molecular sciences · 2021Review
- An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo.Vaccines · 2021Review
- Nanoparticle cancer vaccines: Design considerations and recent advances.Asian journal of pharmaceutical sciences · 2020Review
- Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells.ACS applied materials & interfaces · 2020Article
- Clickable modular polysaccharide nanoparticles for selective cell-targeting.Carbohydrate polymers · 2020Article
- Opportunities and Challenges in the Delivery of mRNA-based Vaccines.Pharmaceutics · 2020Review
- Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.ACS nano · 2019Article
- Messenger RNA translation enhancement by immune evasion proteins: a comparative study between EKB (vaccinia virus) and NS1 (influenza A virus).Scientific reports · 2019Article
- Emerging Nano-/Microapproaches for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Review
- Delivery technologies for cancer immunotherapy.Nature reviews. Drug discovery · 2019Review
- Article
- Turning the corner on therapeutic cancer vaccines.NPJ vaccines · 2019Review
- Formulation, characterization and evaluation of mRNA-loaded dissolvable polymeric microneedles (RNApatch).Scientific reports · 2018Article
- Modulation of mRNA Translation and Cell Viability by Influenza A Virus Derived Nonstructural Protein 1.Nucleic acid therapeutics · 2018Article
- Latest development on RNA-based drugs and vaccines.Future science OA · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Use of mRNA-based vaccines for tumour immunotherapy has gained increasing attention in recent years. A growing number of studies applying nanomedicine concepts to mRNA tumour vaccination show that the mRNA delivered in nanoparticle format can generate a more robust immune response. Advances in the past decade have deepened our understanding of gene delivery barriers, mRNA's biological stability and immunological properties, and support the notion for engineering innovations tailored towards a more efficient mRNA nanoparticle vaccine delivery system. In this review we will first examine the suitability of mRNA for engineering manipulations, followed by discussion of a model framework that highlights the barriers to a robust anti-tumour immunity mediated by mRNA encapsulated in nanoparticles. Finally, by consolidating existing literature on mRNA nanoparticle tumour vaccination within the context of this framework, we aim to identify bottlenecks that can be addressed by future nanoengineering research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.